NaaS Technology Inc. Received Nasdaq Notification Regarding Minimum Market Value Deficiency

NaaS Technology Inc. Received Nasdaq Notification Regarding Minimum Market Value Deficiency

BEIJING, June 21, 2025 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S.-listed EV charging service company in China, today announced that it has received written notification (the "MVLS Notice") from the...

RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis

RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis

YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from European Medicines...

The 3rd Tallest Office Building in Hong Kong Central Plaza Awarded 4 Platinum Building Certifications

The 3rd Tallest Office Building in Hong Kong Central Plaza Awarded 4 Platinum Building Certifications

Acknowledgement as a Green and Sustainable Grade-A Office Building Committed to Optimising Service Quality in a Comfortable Environment HONG KONG, June 11, 2025 /PRNewswire/ -- Central Plaza in Wan Chai is pleased to announce it has been awarded...

VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.

VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.

HONG KONG and WENZHOU, China, June 10, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today that it received written...

33 Financial Group Launches Groundbreaking Shopping Mall Dining Gift Card Receives Prestigious UnionPay Gold Award for Transaction Volume Leadership

33 Financial Group Launches Groundbreaking Shopping Mall Dining Gift Card Receives Prestigious UnionPay Gold Award for Transaction Volume Leadership

HONG KONG, June 9, 2025 /PRNewswire/ -- 33 Finance (SVF License No.: SVF0010), Hong Kong's leading gift card provider, announced the launch of its first dining gift card "Food Pass in Delight" in collaboration with ELEMENTS. The company was...

ESR Secures Top International Design Awards for the Fourth Year Running, Setting New Industry Benchmarks in 2025

ESR Secures Top International Design Awards for the Fourth Year Running, Setting New Industry Benchmarks in 2025

WILMINGTON, Del., March 13, 2025 /PRNewswire/ -- ESR, a leading tech accessories brand, has been once again recognized for its commitment to innovation and design excellence by securing prestigious international design awards in 2025. The company's...

AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration

AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration

Launch of Major Product Expected to Significantly Drive Performance Growth HONG KONG, March 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 12, 2025, the company's...

Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)

Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)

Bringing New Hope to Chinese Dialysis Patients with Hyperphosphatemia SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary,...

Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer

Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer

SUZHOU, China, Dec. 27, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National Medical...

menu
menu